Terlipressin Dosing for Hepatorenal Syndrome

Initial Dosing Regimen

The American College of Cardiology and European guidelines recommend starting terlipressin at 1 mg IV bolus every 4-6 hours combined with albumin, with a maximum dose of 12 mg/day 1, 2
The initial dosing regimen is 1 mg IV bolus every 4-6 hours (total 4-6 mg/day), always combined with albumin, as recommended by the American and European guidelines 1, 2
An alternative approach is continuous IV infusion starting at 2 mg/day, which provides equal efficacy with lower total daily doses and potentially fewer ischemic side effects compared to bolus dosing, according to the American College of Cardiology 1

The American College of Cardiology recommends that terlipressin must always be combined with albumin to optimize circulatory function and treatment efficacy 1, 2
The albumin dosing schedule is 1 g/kg IV on day 1 (maximum 100 g) and 20-40 g/day thereafter until treatment completion, as recommended by the American College of Cardiology and European guidelines 1, 2

If serum creatinine has not decreased by at least 25% from baseline by day 3-4, the American College of Cardiology recommends increasing the dose to 2 mg IV every 4-6 hours (total 8-12 mg/day) 1, 2
The maximum dose is 12 mg/day regardless of administration method (bolus or continuous infusion), as recommended by the American College of Cardiology 1

The median time to response is 14 days, with shorter response times in patients with lower baseline serum creatinine, according to the European guidelines 2
Monitor serum creatinine daily, looking for ≥25-30% reduction by days 3-4 as a marker of treatment response, as recommended by the American College of Cardiology 1
Complete response is defined as serum creatinine returning to within 0.3 mg/dL of baseline, while partial response is defined as regression of AKI stage with serum creatinine ≥0.3 mg/dL from baseline or ≥25% reduction in creatinine, according to the American College of Cardiology 1

Favorable prognostic factors include baseline serum bilirubin <10 mg/dL, baseline serum creatinine <5 mg/dL, and MAP increase ≥5-10 mmHg by day 3, as recommended by the American College of Cardiology and European guidelines 1, 2

Obtain baseline assessment before initiating treatment, including baseline oxygen saturation, baseline electrocardiogram, and ACLF grade and volume status assessment, as recommended by the American College of Cardiology 1
Monitor for ischemic complications, which occur in approximately 12% of patients, and respiratory failure, which occurs in 14-30% of patients, according to the European guidelines and American College of Cardiology 1, 2

Terlipressin can be safely administered via peripheral IV line in ward or ICU settings without requiring central line placement in most patients, as recommended by the American College of Cardiology 1
ICU monitoring is required for patients with ACLF grade 3 (≥3 organ failures) due to increased risk of respiratory failure, according to the American College of Cardiology 1

If terlipressin is ineffective or contraindicated, the American College of Cardiology recommends switching to norepinephrine 0.5 mg/hour (or 5 μg/min) continuous IV infusion, titrated up to 3 mg/hour (or 10 μg/min) to achieve MAP increase >10 mmHg above baseline 1, 3

Each 1 mg/dL reduction in creatinine reduces mortality risk by 27%, even with partial response, according to the American College of Cardiology 3
Treatment with terlipressin improves renal function in 40-50% of patients with type 1 HRS, as recommended by the European guidelines 2